Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Labcorp (LH)

Labcorp appoints John H. Sampson, M.D., Ph.D., to its Board of Directors

Neutral Impact 2 of 5 leadership Written later

Labcorp Holdings appointed John H. Sampson, M.D., Ph.D., as a board member effective February 9, 2026, and named him to the Quality and Compliance Committee. Sampson is vice chancellor for health affairs and dean of the University of Colorado Anschutz School of Medicine and previously held senior leadership roles at Duke University Health System. The filing describes a board addition with no financial results, guidance or deal terms attached.

Key points

  • Board appointment effective February 9, 2026; Board approved the appointment on February 6, 2026
  • Sampson joins the Quality and Compliance Committee
  • Sampson will receive director compensation under the company's program described in its April 4, 2025 proxy statement
  • Sampson is vice chancellor for health affairs and dean at the University of Colorado Anschutz School of Medicine

The filing

CompanyLabcorp (LH)
Form8-K, current report
Filed with the SECFeb 9, 2026, 8:34 AM ET
Accession number0000920148-26-000019

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:10 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 09, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.